ClinicalTrials.gg
CompletedNCT03782116Updated Jan 13, 2025Results posted

Stress Incontinence Trial With Elitone Device

An interventional study of Transcutaneous electrical stimulation (Elitone) in Stress Urinary Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to female participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Enrollment
90th of 164
87 · median 99
Started
2018
with 9 others
No phase
109 of 190
18 open now
Registered
108th of 190
by date

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 90th largest by enrollment of the 164 interventional ones that give a count, is one of 10 that started in 2018, is one of 109 with no phase, and was the 108th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 21 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with mild-moderate stress urinary incontinence.

Read the detailed description

The Elitone device delivers electrical muscle stimulation to pelvic floor muscles through a disposable surface electrode shaped to fit the perineal region. In typical use women self-administer treatment 20 minutes per day, 5x per week, for 6-12 weeks. Elidah is initiating a prospective, randomized clinical study to demonstrate device efficacy. The study expands a similar pilot to 60 subjects, adds a control arm (sham device) and includes additional outcome measures. Like the earlier study, subjects will self-administer treatment over multiple weeks while maintaining daily logs of their treatment and incontinence symptoms. This is a home-use study, which does not require clinic visits. Accordingly, this allows subject recruitment from across US.

03

Conditions studied

  • Stress Urinary Incontinence
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Predominant Mild-moderate stress incontinence symptoms as determined by self-reported typical number of accidents of 1 per 24 hours or more.

Exclusion criteria

Exclusion Criteria:

  • Severe incontinence as determined by self-reported >5 accidents in 24-hr period
  • Currently pregnant, may be pregnant, attempting to become pregnant, or delivery within previous 6 weeks
  • Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
  • Cancer, epilepsy or cognitive dysfunction
  • Vaginal or pelvic surgery within previous 6 months
  • Complete denervation of the pelvic floor
  • History or symptoms of urinary retention, extra-urethral incontinence, overflow incontinence
  • Active urinary tract infection (UTI) or history of recurrent UTIs (more than three in a year)
  • Recurrent vaginitis (bacterial/fungal)
  • Pelvic pain/painful bladder syndrome
  • Underlying neurologic/neuromuscular disorder
  • Severe Obesity as defined by >= 35
  • Chronic coughing
  • Impaired decision making, drug or alcohol dependence, or suicidal thoughts.
  • Anyone who lacks the capacity to consent for themselves or who requires a legal representative to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Treatment

    Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz)

    Device: Transcutaneous electrical stimulation (Elitone)

  • Sham comparator
    Control

    Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles.

    Device: Transcutaneous electrical stimulation (Elitone)

Interventions

  • DeviceTranscutaneous electrical stimulation (Elitone)

    Transcutaneous perineal area electrical stimulation

    Also known as: Elitone

06

What researchers measure

Primary outcomes

  1. Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes

    The percent reduction in average number of urinary incontinence episodes over 12 weeks.

    Time frame: 12 weeks

Secondary outcomes

  1. Efficacy Assessed by Percent Reduction in Average Pad Weight

    The percent reduction of pad weight in a day over the 12 weeks.

    Time frame: 12 weeks

  2. Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)

    The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome.

    Time frame: 12 weeks

  3. Pads Per Day

    Reduction of number of pads used per day

    Time frame: 12 weeks

07

Results

Posted Jan 13, 2025

Participant flow

Completed Intervetion
Participant flow — Completed Intervetion
MilestoneTreatmentControl
Started5730
Completed4018
Not completed1712
Withdrew: Lost to follow-up117
Withdrew: Withdrawal by subject65
Included in Analysis
Participant flow — Included in Analysis
MilestoneTreatmentControl
Started4018
Completed3513
Not completed55
Withdrew: Protocol violation55

Outcome measures

PrimaryEfficacy Assessed by Percent Reduction in Urinary Incontinence Episodes

The percent reduction in average number of urinary incontinence episodes over 12 weeks.

Time frame:
12 weeks
Reported as:
Mean · percent reduction in leaks/day
Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes
percent reduction in leaks/dayTreatmentControl
Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes52.8 ± 36.37.9 ± 55.9
SecondaryEfficacy Assessed by Percent Reduction in Average Pad Weight

The percent reduction of pad weight in a day over the 12 weeks.

Time frame:
12 weeks
Reported as:
Mean · percentage reduction in pad weight
Efficacy Assessed by Percent Reduction in Average Pad Weight
percentage reduction in pad weightTreatmentControl
Efficacy Assessed by Percent Reduction in Average Pad Weight38.3 ± 62.425.3 ± 48.8
SecondaryEfficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)

The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome.

Time frame:
12 weeks
Reported as:
Mean · Change of score on a scale
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)
Change of score on a scaleTreatmentControl
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)20.8 ± 20.810.3 ± 21.8
SecondaryPads Per Day

Reduction of number of pads used per day

Time frame:
12 weeks
Reported as:
Mean · percentage reduction
Pads Per Day
percentage reductionTreatmentControl
Pads Per Day35.0 ± 34.18.2 ± 59.9

Adverse events

Collected over Duration of the 12-week study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/35 (0%)0/35 (0%)1/35 (2.9%)
Control0/13 (0%)0/13 (0%)0/13 (0%)
Most frequent other events
Most frequent other events
EventTreatmentControl
Transient muscle painMusculoskeletal and connective tissue disorders1/350/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)TreatmentControlTotal
Mean48.7 ± 13.344.7 ± 7.047.6 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentControlTotal
Female351348
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TreatmentControlTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)TreatmentControlTotal
United States351348
Stress incontinence leaks/day
Stress incontinence leaks/day(leaks/day)TreatmentControlTotal
Mean2.81 ± 1.012.65 ± 1.172.76 ± 1.05
08

Study locations

1 site
  • Nationwide At-Home study
    Monroe, Connecticut 06468, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Mar 2019, 6 months.

Results were first posted in Jan 2025, 5 years 9 months after primary completion.

Of 41 industry-sponsored interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 53. This study's 6 months is below that.

Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Dec 20, 2018
StartActual
Sep 1, 2018
Primary completionActual
Mar 31, 2019
CompletionActual
Mar 31, 2019
Results first posted
Jan 13, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03782116
Lead sponsor
Elidah, Inc.
Responsible party
Sponsor
First posted
Dec 20, 2018
Start date
Sep 1, 2018
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019
Results posted
Jan 13, 2025
Last update
Jan 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion